Classification of Substrates and Inhibitors of P-Glycoprotein Using Unsupervised Machine Learning Approach

P-glycoprotein (P-gp), a drug efflux pump, affects the bioavailability of therapeutic drugs and plays a potentially important role in clinical drug-drug interactions. Classification of candidate drugs as substrates or inhibitors of the carrier protein is of crucial importance in drug development. Accurate classification is difficult to achieve due to two major factors: i. The extreme diversity of substrates and the presence of multiple binding sites complicate the understanding of the mechanisms behind and hinder the development of a true, conclusive quantitative structure-activity relationship (QSAR) for P-gp substrates. ii. Both inhibitors and substrates interact with the same binding site of P-gp, as a result, it is not surprising that both share many common structural features. In this work, an unsupervised machine learning approach based on the Kohonen self-organizing maps (SOM) was explored, which incorporated a predefined set of physicochemical descriptors encoding the key molecular properties capable of discerning a substrate from an inhibitor. The SOM model can discriminate between substrates and inhibitors with an average accuracy of 82.3%. The current results show that the SOM-based method provides a potential in silico model for virtual screening.

[1]  Ying Xue,et al.  Prediction of P‐Glycoprotein Substrates by a Support Vector Machine Approach. , 2004 .

[2]  Samuel Kaski,et al.  Visualizing the Clusters on the Self-Organizing Map , 1994 .

[3]  Y. Shao,et al.  Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. , 1996, Biochimica et biophysica acta.

[4]  Jung-Han Kim,et al.  Capillary electrophoretic profiling and pattern recognition analysis of urinary nucleosides from thyroid cancer patients , 2003 .

[5]  Yan Li,et al.  Comparison of steroid substrates and inhibitors of P-glycoprotein by 3D-QSAR analysis , 2005 .

[6]  Lutz Schmitt,et al.  Structure and mechanism of ABC transporters. , 2002, Current opinion in structural biology.

[7]  Erik Evensen,et al.  A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. , 2002, Journal of medicinal chemistry.

[8]  Tatiana Nikolskaya,et al.  Modeling of human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach. , 2003, Journal of medicinal chemistry.

[9]  D K Yu,et al.  The Contribution of P‐glycoprotein to Pharmacokinetic Drug‐Drug Interactions , 1999, Journal of clinical pharmacology.

[10]  Mohammad Bagher Menhaj,et al.  Training feedforward networks with the Marquardt algorithm , 1994, IEEE Trans. Neural Networks.

[11]  I K Pajeva,et al.  Structure-activity relationships of multidrug resistance reversers. , 2001, Current medicinal chemistry.

[12]  L. Bain,et al.  Structure-activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein. , 1997, Environmental health perspectives.

[13]  S. Ekins,et al.  Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. , 2002, Molecular pharmacology.

[14]  A. Safa,et al.  Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. , 2004, Current medicinal chemistry. Anti-cancer agents.

[15]  C. Dey,et al.  P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. , 2003, Pharmacological research.

[16]  Kai Huang,et al.  Feature reduction for improved recognition of subcellular location patterns in fluorescence microscope images , 2003, SPIE BiOS.

[17]  V. Ling,et al.  Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. , 1997, European journal of biochemistry.